Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | PDE6D | O43924 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14334566 | 1.00 | HMGCR (0.53) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL15976652 | 1.00 | HMGCR (0.53) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3429 | 1.00 | HMGCR (0.53) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL16401450 | 0.93 | HMGCR (0.52) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL15976641 | 0.93 | HMGCR (0.52) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL7093034 | 0.93 | HMGCR (0.52) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL18979348 | 0.92 | HMGCR (0.60) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL12609138 | 0.92 | HMGCR (0.43) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL12130486 | 0.92 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL16401418 | 0.90 | HMGCR (0.49) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011121598-A1 | CRYSTALLINE 7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-(METHANESULFONYL-METHYL-AMINO)-PYRIMIDIN-5-YL]-3(R)-HYDROXY-5-OXO-HEPT-6-ENOIC ACID METHYL ESTER AND PROCESS THEREOF | BIOCON LIMITED (IN) | 2011-10-06 | — | — | WO | claimed |
| WO-2008093205-A2 | A METHOD FOR THE PURIFICATION OF ROSUVASTATIN INTERMEDIATE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2008-08-07 | — | — | WO | claimed |
| WO-2011121598-A1 | CRYSTALLINE 7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-(METHANESULFONYL-METHYL-AMINO)-PYRIMIDIN-5-YL]-3(R)-HYDROXY-5-OXO-HEPT-6-ENOIC ACID METHYL ESTER AND PROCESS THEREOF | BIOCON LIMITED (IN) | 2011-10-06 | — | — | WO | disclosed |
| US-7655796-B2 | Process for the preparation of rosuvstatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-02-02 | — | — | US | disclosed |
| WO-2008093205-A2 | A METHOD FOR THE PURIFICATION OF ROSUVASTATIN INTERMEDIATE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2008-08-07 | — | — | WO | disclosed |
| US-7179916-B2 | Process for the preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-02-20 | — | — | US | disclosed |
| EP-1673351-A1 | A PROCESS FOR THE PREPARATION OF ROSUVASTATIN INVOLVING A TEMPO-MEDIATED OXIDATION STEP | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-06-28 | — | — | EP | disclosed |
| US-20060089501-A1 | Process for the preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-04-27 | — | — | US | disclosed |
| WO-2006017357-A1 | A PROCESS FOR THE PREPARATION OF ROSUVASTATIN INVOLVING A TEMPO-MEDIATED OXIDATION STEP | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-02-16 | — | — | WO | disclosed |
| US-RE37314-E1 | Pyrimidine derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-08-07 | — | — | US | disclosed |
| EP-0521471-B1 | Pyrimidine derivatives as HMG-CoA reductase inhibitors | SHIONOGI & CO (JP) | 2000-10-25 | — | — | EP | disclosed |
| US-5260440-A | Anticholesterol agents | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-11-09 | — | — | US | disclosed |
| EP-0521471-A1 | Pyrimidine derivatives as HMG-CoA reductase inhibitors | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089501-A1 | Process for the preparation of rosuvastatin | HMGCR, PCSK9, CETP | HMGCR 1/4885ALDH1A1 2920/4885CYP3A4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.